Activates nuclear SREBP-2 expression and up-regulates HMGCR for killing bladder cancer cells (147)  Blocks SREBP-2-mediated cholestergenesis, and inhibits SREBP-1-mediated lipogenesis (132)  Inhibits EMT targeting of Twist1 to block tumor progression (135). Here, SREBF1 is linked to urinary bladder carcinoma.